BERGEM·HEALTH
Home › Treatments › Oncology
Oncology
SPECIALITY · ONCOLOGY

Oncology in Türkiye — tumour board in 72 hours, immunotherapy and targeted therapy.

Multidisciplinary plan from Memorial, Liv Hospital and Akdeniz professors. Direct access, no agency markup.

What you get
  • Multidisciplinary tumor board decision within 72 hours
  • Immunotherapy and targeted therapy programmes
  • Direct access to professors at Memorial, Liv and Akdeniz
  • English-speaking coordinator and translator throughout
6 hospitals · 12 oncology professors · NCCN/ESMO protocols
New: CAR T-cell therapy at our partner Akdeniz University (Antalya). Türkiye's first university-based CAR-T and cellular-therapies production centre has completed its licensing and is preparing for its first patients — established CAR T for blood cancers, with clinical-trial programmes for some solid tumours now concluding. Read the complete CAR T-cell therapy guide →   See the announcement
SECOND OPINION ONLINE

Tumor board second opinion — within 72 hours, free

Send your recent imaging, biopsy, and treatment history — a 5-specialist tumor board returns a written plan in 72 hours, free of charge.

01
Upload your discharge summary
Discharge summaries, CT/MRI discs (DICOM), histology slides if available. Up to 200 MB.
02
Coordinator reviews
Selects 2–3 professors matched to your diagnosis and stage. Sends them your records.
03
Video consultation
The professor responds online — review of histology, protocol, travel plan if needed.
What to send
  • Discharge summaries from inpatient / outpatient care
  • CT or MRI — original DICOM discs
  • Histology report (if available)
  • Slides or blocks for review (optional)
  • Current therapy list
Request a second opinion
Free. Confidential. Anna Moroz reads every request personally.
11 PROCEDURES

What we treat in oncology

Full scope of solid tumors and hematologic malignancies, multidisciplinary tumor board within 72 hours.

TREATMENT METHODS

Treatment methods in oncology

NCCN/ESMO protocols, immunotherapy, targeted therapy guided by NGS, modern radiation (SBRT, SRS, VMAT).

Multidisciplinary tumor board (MDT)
Surgeon + medical oncologist + radiation oncologist + radiologist + pathologist convene per case.
6 clinics
Immunotherapy (checkpoint inhibitors)
Pembrolizumab, nivolumab, atezolizumab, ipilimumab. PD-L1/MSI guided.
5 clinics
Targeted therapy (NGS-guided)
Next-generation sequencing to find actionable mutations; FDA/EMA-approved targeted agents.
4 clinics
SBRT / SRS / VMAT
Stereotactic body radiotherapy, stereotactic radiosurgery, volumetric modulated arc therapy.
5 clinics
Surgical oncology (organ-sparing)
Da Vinci robotic surgery, laparoscopic resections, breast-conserving operations.
6 clinics
CAR-T & advanced cell therapy
CAR-T cell therapy for relapsed/refractory lymphomas in select centres. Our partner Akdeniz University in Antalya — Türkiye's first university-based CAR-T production centre — has completed licensing and is preparing to treat its first patients.
1 clinic
Chemotherapy (cytotoxic + targeted)
Day-hospital infusion centre, NCCN/ESMO regimens.
6 clinics
ONCOLOGY · TEAM

Professors you get direct access to

Professors and senior specialists at Memorial, Liv and Akdeniz. Direct contact, no middlemen.

Prof. Dr. Mustafa Özdoğan
Prof. Dr. Mustafa Özdoğan
Professor of Medical Oncology
Memorial Göztepe Hospital, Istanbul
Prof. Dr. Aylin Fidan Korcum Şahin, MD
Prof. Dr. Aylin Fidan Korcum Şahin, MD
Professor of Radiation Oncology, Department Chair
Akdeniz University Hospital
Prof. Dr. Nasuh Utku Doğan
Prof. Dr. Nasuh Utku Doğan
Professor of gynaecological oncology, private practice
Private practice, Antalya
Prof. Dr. Ömer Kutlu
Prof. Dr. Ömer Kutlu
Professor and Head of the Andrology Unit, Department of Urology
Akdeniz University Hospital, Antalya
Doç. Dr. Hakan Çakın
Doç. Dr. Hakan Çakın
Associate professor at the Department of Neurosurgery
Akdeniz University Hospital, Antalya
Prof. Dr. Mustafa Karaca
Prof. Dr. Mustafa Karaca
Professor at the Department of Medical Oncology
Akdeniz University Faculty of Medicine, Antalya
Prof. Dr. Erdal Karaöz
Prof. Dr. Erdal Karaöz
Director of the Centre for Regenerative Medicine and Stem Cells
Liv Hospital Ulus, Istanbul
Prof. Dr. Muhittin Yaprak
Prof. Dr. Muhittin Yaprak
Professor at the Department of General Surgery
Akdeniz University Hospital, Antalya
KP
Prof. Dr. Kamil Yalçın Polat
Chair of the Organ Transplant Centre, Memorial Bahçelievler Hospital; head of the transplant and general surgery centre at Memorial Ataşehir
Memorial Bahçelievler Hospital
Prof. Dr. Koray Acarlı
Prof. Dr. Koray Acarlı
Professor at the Department of General and Hepatopancreatobiliary (HPB) Surgery
Liv Hospital Ulus, Istanbul
Prof. Dr. Meral Günaldı
Prof. Dr. Meral Günaldı
Professor of Medical Oncology
Liv Hospital Ulus, Istanbul
Prof. Dr. Selen Doğan
Prof. Dr. Selen Doğan
Professor at the Department of Obstetrics & Gynaecology, Gynaecologic Oncology Unit
Akdeniz University Hospital, Antalya
Prof. Dr. Cumhur Arıcı
Prof. Dr. Cumhur Arıcı
Professor at the Department of General Surgery; Head of the Endocrine Surgery Unit
Akdeniz University Hospital, Antalya
YE
Prof. Dr. Yeliz Emine Ersoy
Breast and endocrine surgeon, Memorial Bahçelievler Hospital; formerly professor of general surgery, Bezmialem Vakıf University
Memorial Bahçelievler Hospital
Dİ
Doç. Dr. Ahmet Yalın İşcan
Endocrine surgeon, Memorial Bahçelievler Hospital; associate professor of general surgery, Istanbul University Istanbul Faculty of Medicine
Memorial Bahçelievler Hospital
Doç. Dr. Mustafa Kaplan
Doç. Dr. Mustafa Kaplan
Urologist, Liv Hospital Bahçeşehir
İSÜ Liv Hospital Bahçeşehir
Doç. Dr. Murat Ayhan
Doç. Dr. Murat Ayhan
Medical oncologist
Liv Hospital Vadistanbul
DD
Doç. Dr. Hülya Dirol
Associate Professor of Chest Diseases, Akdeniz University Faculty of Medicine
Akdeniz University Hospital
GÇ
Prof. Dr. Güven Çetin
Adult haematologist, Memorial Bahçelievler Hospital; formerly head of haematology, Bezmialem Vakıf University Faculty of Medicine
Memorial Bahçelievler Hospital
Prof. Dr. Gonca Kara Gedik
Prof. Dr. Gonca Kara Gedik
Professor of Nuclear Medicine, Department of Nuclear Medicine
Akdeniz University Hospital
EE
Prof. Dr. Evrim Erdemoğlu
Gynaecologic oncologist, Memorial Antalya Hospital; formerly head of the gynaecologic oncology division, Süleyman Demirel University Faculty of Medicine
Memorial Antalya Hospital
Doç. Dr. Tuğba Başoğlu Tüylü
Doç. Dr. Tuğba Başoğlu Tüylü
Associate Professor of Medical Oncology
Memorial Göztepe Hospital
Doç. Dr. Sümeyre Seda Ertekin
Doç. Dr. Sümeyre Seda Ertekin
Associate Professor of Dermatology
Memorial Göztepe Hospital
Prof. Dr. Salih Taşkın
Prof. Dr. Salih Taşkın
Professor of Obstetrics and Gynaecology
Memorial Göztepe Hospital

All 98 professors and doctors in this speciality

DIAGNOSTICS

Oncology diagnostics

PET-CT, multiparametric MRI, NGS, liquid biopsy and expert pathology — typically completed within 5–10 days.

PET-CT (FDG, PSMA, Ga-68 DOTATATE)
Whole-body staging and restaging with multiple radiotracers.
1 day
MRI 3T (with diffusion + spectroscopy)
Brain, breast, prostate (multiparametric), liver, pelvis.
1 day
Biopsy & molecular pathology
IHC + FISH + MSI status + tumor grading by experienced pathologists.
3–5 days
NGS panel (Next-Gen Sequencing)
500+ gene panel to find actionable mutations.
10–14 days
EBUS-TBNA / EUS-FNA
Endoscopic ultrasound-guided sampling of mediastinal/abdominal lesions.
1 hour
Liquid biopsy (ctDNA)
Blood-based monitoring of tumor DNA for treatment response.
7–10 days
Tumor markers panel
CA 15-3, CA 19-9, CEA, AFP, PSA, CA 125 with quality control.
1 day
PRICE SNAPSHOT

Oncology pricing — Türkiye vs EU/USA

Minimum prices, for reference only. The final cost is calculated individually after the doctors review your records.

Procedure Türkiye EU / USA Savings
Tumor board second opinion Free $1 500 – 3 500 −100%
PET-CT (whole body) from $800 $3 500 – 7 000 −75%
NGS panel (500+ genes) from $1 800 $8 000 – 15 000 −75%
Immunotherapy (3 cycles pembrolizumab) from $6 000 $30 000 – 60 000 −80%
Breast cancer surgery + reconstruction from $12 000 $40 000 – 100 000 −75%
CAR-T cell therapy from $120 000 $400 000 – 600 000 −65%
Chemotherapy cycle from $800 $5 000 – 12 000 −80%
The information on this page is for reference only and does not constitute a medical opinion.
Request a precise quote for my case
QUESTIONS

Frequently asked about Oncology

Tumor board decision — what is in it?
A written treatment plan from 5 specialists (surgeon, medical oncologist, radiation oncologist, radiologist, pathologist) within 72 hours. Includes staging confirmation, recommended sequence (surgery first vs. neoadjuvant chemo), specific drug regimens, and expected timeline.
Immunotherapy — am I eligible?
Depends on tumor type, PD-L1 status, MSI status, and prior treatments. Most lung, melanoma, kidney, bladder and many GI cancers have approved immunotherapy options. We review your biopsy and run PD-L1 IHC if not already done.
Proton therapy — when is it preferred over IMRT?
Pediatric cancers, base-of-skull tumors, ocular melanoma, and selected re-irradiations. Reduces dose to surrounding healthy tissue. Decision made by the radiation oncology team based on dosimetry simulation. Our partner hospitals do not offer proton therapy, and it is not yet available in Türkiye — if it is clearly the better option for you, the tumor board will tell you.
Second opinion — what to send?
Recent imaging (CT, MRI, PET-CT), pathology slides or report, prior treatment history, current medications, and any genetic/molecular tests. We arrange remote review and return a written second opinion within 72 hours.
Am I eligible for CAR-T cell therapy and is it available in Turkey?
Approved CAR-T products cover relapsed/refractory large B-cell lymphoma (from second line for early relapse), mantle-cell and follicular lymphoma, B-ALL (tisagenlecleucel up to age 25; brexucabtagene in adults) and multiple myeloma (ide-cel, cilta-cel, after 1–2 prior lines). Eligibility depends on the product and on local approval. In Türkiye, CAR-T is given at specialised cellular-therapy centres; our partner Akdeniz University has licensed local production and is preparing for its first patients. CRS and ICANS are managed in dedicated cellular therapy units; in pivotal trials, complete response rates ranged from roughly 30–40% to over 80% depending on the disease and product, and responses are not guaranteed.
When is liquid biopsy (ctDNA) ordered and what does it add to tissue biopsy?
Liquid biopsy is used when tissue is insufficient, the tumor is inaccessible, or rapid genotyping is needed at progression, particularly in NSCLC, colorectal and breast cancer. It detects actionable mutations (EGFR, KRAS, BRAF, ESR1) with sensitivity 70-85% and turnaround of 7-10 days versus 14-21 for tissue NGS. ctDNA is also used for minimal residual disease monitoring after curative surgery.
How does NGS-guided targeted therapy change my treatment plan?
Comprehensive NGS (500+ genes) identifies actionable alterations in roughly 40% of solid tumors — KRAS G12C (sotorasib, adagrasib), EGFR exon 19/L858R (osimertinib), ALK (alectinib, lorlatinib), ROS1 (crizotinib, entrectinib, repotrectinib), BRAF V600E (dabrafenib-trametinib, encorafenib); HER2-low status (for trastuzumab deruxtecan) is assessed by IHC. Results are reviewed at the molecular tumor board within 10-14 days, and FDA/EMA-approved targeted agents are matched before chemotherapy where possible.
REQUEST

Tell me about your case — I’ll read it personally.

Fill in the short form on the consultation page — diagnosis, preferred timing, attached records. We assemble a tumour board for your case and reply within 4 hours.

Open the consultation form
  • Reply within 4 hours during business hours
  • Confidentiality guaranteed
  • Coordinator-translator inside the doctor’s office
  • Tumour board of 2–3 professors within 72 hours